Search Within

Craig Moskowitz

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (14)
  3. Research Letter (1)
Groups
  1. Department of Medicine (35)
  2. Department of Pathology and Laboratory Medicine (35)
  3. Hematologic Malignancies, Division of (35)
  4. Center for Hematologic Malignancies (27)
  5. Lymphoma (27)
  6. Epidemiology and Biostatistics (23)

More Groups

People
  1. Ahmet Dogan (22)
  2. Andrew Zelenetz (21)
  3. Anas Younes (18)
  4. Matthew Matasar (15)
  5. Connie Batlevi (12)
  6. Paul Hamlin (12)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (4)
  6. 2018 (3)

More Years

Publications
  1. Blood (14)
  2. Journal of Clinical Oncology (3)
  3. Blood Cancer Journal (2)
  4. Clinical Cancer Research (2)
  5. Haematologica (2)
  6. Applied Immunohistochemistry & Molecular Morphology (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. American Association for Cancer Research (3)
  3. American Society of Clinical Oncology (3)
  4. Elsevier Inc. (3)
  5. Nature Publishing Group (3)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
    Journal Article

    Yahalom, J.; Xu, A. J.; Noy, A.; Lobaugh, S.; Chelius, M.; Chau, K.; Portlock, C.; Hajj, C.; Imber, B. S.; Straus, D. J.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse
    Journal Article

    Kumar, A.; Sha, F.; Toure, A.; Dogan, A.; Ni, A.; Batlevi, C. L.; Palomba, M. L. M.; Portlock, C.; Straus, D. J.; Noy, A.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save
  • Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
    Journal Article

    Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P.; Moskowitz, C.; Pichardo, J.; Portlock, C.; Sha, F.; Zelenetz, A. D.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save